Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Foghorn Therapeutics (FHTX) has issued an announcement.
Foghorn Therapeutics Inc. has appointed Kristian F. Humer as their new Chief Financial Officer, bringing a wealth of experience from his previous role at Viridian Therapeutics and a strong background in healthcare investment banking with Citi, Lehman Brothers, UBS, and Merrill Lynch. Humer, who also serves on the board of Sensei Biotherapeutics, will receive a competitive compensation package, including a $475,000 base salary, potential for a 40% performance bonus, a $87,000 signing bonus, and an option to purchase 275,000 company shares. His appointment, effective immediately, marks a strategic move for Foghorn as they navigate the financial landscape of the biotechnology sector.
See more insights into FHTX stock on TipRanks’ Stock Analysis page.